Business Context and Reporting Period
This Form 8-K filing by Ardelyx, Inc. (ARDX) reports a significant executive appointment. The report date is October 13, 2025, with the event occurring on the same date.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation details:
- Base Salary: $550,000 annually.
- Target Bonus: 45% of base salary (pro-rated for 2025).
- Sign-on Bonus: $180,000.
- Housing Consideration: $150,000.
- Equity Grants: 578,104 stock options (exercise price $5.01) and 146,896 restricted stock units (RSUs).
Material Changes
The primary material change is the appointment of Sue Hohenleitner as Chief Financial Officer (CFO) and Principal Financial Officer, effective November 4, 2025. Ms. Hohenleitner joins from Johnson & Johnson, where she most recently served as VP and CFO of J&J Innovative Medicine North America.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, risk factors, or management commentary regarding the company's operational outlook. The document notes that the Company intends to enter into standard indemnification and change in control severance agreements with the new CFO.
Investor Verification Checklist
- Verify the effective start date of the new CFO (November 4, 2025) and the transition plan for the outgoing financial leadership.
- Confirm the total immediate cash outlay for the new CFO ($330,000 in sign-on and housing payments).
- Review the vesting schedule for the 578,104 options and 146,896 RSUs to understand future dilution and retention incentives.
- Check for any pending departure announcements for the previous CFO not included in this specific filing.